张继明

教授,博士生导师,华山医院主任医师

联系方式:办公室电话(021)52888125

Email:jmzhang@fudan.edu.cn

研究方向:感染性疾病的基础与临床研究

教育背景

1984年毕业于新乡医学院,获学士学位

1995年毕业于原上海医科大学(硕博连读),获硕士及博士学位

2004年曾在德国ESSEN大学病毒研究所进修

教学及科研情况

承担感染性疾病学和内科学的教学任务,目前招收内科学(感染病专业)学术型和专业型博士和硕士、护理学(感染病)学术型博士、生物yu2医药工程学博士。已培养研究生40余名,其中博士研究生20名。

近五年来获得国家自然科学基金面上项目3项,科技部传染病重大专项子课题2项、NIH合作课题1项。目前在研国家自然科学基金面上项目2项,NIH国际合作课题1项。发表SCI论文80余篇(包括GUT,Hepatology,J Hepatol. J Virol., PLoS Pathog., Nature Communications, Clin Infect Dis., Theranostics,J Infect Dis.等)。

曾获得教育部自然科学二等奖(2009年),复旦大学优秀研究生导师(2011年),上海市优秀青年医师导师(2018年),复旦大学十佳教师,被授予“钟扬式好老师”称号 (2020年),“一健康基金”优秀教师 (二等奖) (2020年),全国卫生健康系统新冠肺炎疫情防控工作先进个人(2020年),致公党中央抗击新冠肺炎疫情先进个人(2020年),上海市医师协会“仁心医师奖”提名奖(2021)。

学术任职

现任华山医院感染病科副主任,国家传染病医学中心副主任,上海市传染病与生物安全应急响应重点实验室副主任,上海市肝病研究所病毒性肝炎研究室主任。

兼任中华医学会医学病毒分会常委、副秘书长,上海市医学会医学病毒学分会名誉主任委员,上海市医学会肝病学专科分会委员,上海市感染病学专科分会 委员,上海市医师协会感染病学分会 。

近五年主要论文

1. Jing Li#, Lihong Qu#, Xuehua Sun, Yanhong Liu, Qiming Gong, Demin Yu, Donghua Zhang, Jiehong Jiang, Jia Chen, Dong Wei, Yue Han, Yueqiu Gao, Qin Zhang, Weimin She, Liang Chen, Jiming Zhang*, Xinxin Zhang*. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients

2. Jian Sun#; Hongying Guo#; Xueping Yu#; Jingwen Chen#; Haoxiang Zhu; Xun Qi; Xueyun Zhang; Jiajia Han; Xiaoqin Liu; Jianghua Yang; Jiefei Wang; Zhiping Qian; Yuxian Huang; Richeng Mao; Jiming Zhang*. Evaluation of prognostic value of neutrophil-to-lymphocyte ratio in patients with acute-on-chronic liver failure or severe liver injury from chronic HBV infection. Eur J Gastroenterol Hepatol 2021: doi: 10.1097/MEG.0000000000002207

3. Mingjie Wang#; Li Chen#; MinHui Dong#; Jing Li; Beidi Zhu; Zhitao Yang; Qiming Gong; Yue Han; Demin Yu; Donghua Zhang; Fabien Zoulim*; Jiming Zhang*; Xinxin Zhang*. Viral quasispecies quantitative analysis: a novel approach for appraising the immune tolerant phase of chronic hepatitis B virus infection. Emerg Microbes Infect, 2021 10(1):845-851.

4. Sisi Yang; Zhongliang Shen; Yaoyue Kang; Liren Sun; Usha Viswanathan; Hongying Guo; Tianlun Zhou; Xinghong Dai; Jinhong Chang; Jiming Zhang*; Ju-Tao Guo*. A putative amphipathic alpha helix in hepatitis B virus small envelope protein plays a critical role in the morphogenesis of subviral particles. J Virol. 2021 95(8): e02399-20

5. Shilin Yuan#; Guanghong Liao#; Menghuan Zhang#; Yuanfei Zhu#; Kun Wang; Weidi Xiao; Caiwei Jia; Minhui Dong; Na Sun; Axel Walch; Ping Xu*; Jiming Zhang*; Qiang Deng*; Ronggui Hu*. Translatomic profiling reveals novel self-restricting virus-host interactions during HBV infection. J Hepatol. 2021 75(1):74-85

6. Li J, Li J, Chen S, Yuan Q, Zhang J, Wu J, Jiang Q, Wang Q, Xia NS, Zhang J*, Tong S*. Naturally occurring 5' preS1 deletions markedly enhance replication and infectivity of HBV genotype B and genotype C. Gut. 2020 Jun 22: gutjnl-2019-320096. doi:10.1136/gutjnl-2019-320096. Online ahead of print. PMID: 32571971

7. Shen Z, Wu J, Gao Z, Wang J, Zhu H, Mao R, Wang X, Zhang J*, Xie Y*, Liu J*. Characterization of IL-21-expressing recombinant hepatitis B virus (HBV) as a therapeutic agent targeting persisting HBV infection. Theranostics. 2020 Apr 25;10(12):5600-5612. doi:10.7150/thno.44715. eCollection 2020.

8. Shen Z, Liu J, Wu J, Zhu Y, Li G, Wang J, Luo M, Deng Q, Zhang J*, Xie Y*. IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models. Theranostics. 2019 May 31;9(13):3798-3811.

9. Yang F, Yu X, Zhou C, Mao R, Zhu M, Zhu H, Ma Z, Mitra B, Zhao G, Huang Y, Guo H*, Wang B*, Zhang J*. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. PLoS Pathog. 2019 Apr 18;15(4): e1007690.

10. Zhang Y, Zhang H, Zhang J, Zhang J*, Guo H*. Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate. Antiviral Res. 2019 May; 165:47-54.

11. Mitra B, Wang J, Kim ES, Mao R, Dong M, Liu Y, Zhang J*, Guo H*. Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation. J Virol. 2019 Jun 14;93(13). pii: e00196-19.

12. Jia W, Zhu MQ, Qi X, Wang T, Wen X, Chen PD, Fan QQ, Zhang WH, Zhang JM*. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. Virol J. 2019 May 7;16(1):61-68.

13. Jiang PX, Mao RC, Dong MH, Yu XP, Xun Q, Wang JY, Jing L, Qiang D, Zhang JM*. Exonuclease I and III improve the detection efficacy of hepatitis B virus covalently closed circular DNA. Hepatobiliary Pancreat Dis Int. 2018 Nov 22. pii: S1499-3872(18)30261-3.

14. Dong M, Wu J, Yu X, Li J, Yang S, Qi X, Mao R, Zhang Y, Yu J, Zhu H, Yang F, Qin Y, Zhang J*. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients. Liver Int. 2018 Jan 3. doi: 10.1111/liv.13688.

15. Liu H, Li F, Zhang X, Yu J, Wang J, Jia J, Yu X, Shen Z, Yuan Z, Zhang X, Zhang Z, Zhang X, Lu L, Li H, Lu M*, Zhang J*. Differentially expressed intrahepatic genes contribute to control of hepatitis B virus replication in the inactive carrier phase. J Infect Dis. 2018 Jan 2. doi: 10.1093/infdis/jix683.

16. Li J, Zhang TY, Song LW, Qi X, Yu XP, Li FH, Zhou P, Qin YL, Yang L, Zhao JH, Mao RC, Zhang YM, Wang JY, Yang FF, Zhu HX, Yang SS, Huang YX, Yuan Q*, Zhang J, Zhang JM*, Xia NS. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels. Hepatol Res. 2018 Feb;48(3): E133-E145.

17. Shen Z, Yang H, Yang S, Wang W, Cui X, Zhou X, Liu W, Pan S, Liu Y, Zhang J, Zhang J*, Xie Y*, Liu J*. Hepatitis B virus persistence in mice reveals IL-21 and IL-33 as regulators of viral clearance. Nat Commun. 2017 Dec 14;8(1):2119.

科研课题(国家级)

1.2022-2025 国家自然基金面上项目:肝组织内宿主基因ZMYM3通过抑制乙肝病毒X蛋白表达调控cccDNA转录活性的机制研究(编号:8217081522),张继明,课题负责人,55万。

2.2019-2022 国家自然基金面上项目:基于膜蛋白FAM176A的基因治疗方法在慢性乙肝病毒感染动物模型中的抗病毒作用、安全性及其机制研究(编号:81871640),张继明,课题负责人,57万。

3.2017.1-2020.12 国家“十三五”传染病重大专项:基于大样本前瞻性队列的慢性乙型肝炎临床转归的集成干预技术研究(编号:2017ZX10202203007),张继明,课题负责人(任务级),125万。

4.2017.1-2020.12 国家“十三五”传染病重大专项:免疫调节/抗病毒联合治疗新方案提高慢性乙型肝炎临床治愈率及其对远期转归影响的研究(编号:2017ZX10202202),张继明,课题负责人(任务级),181万。

5.2017.1-2020.12 国家自然基金面上项目 剪切刺激因子-2通过PTB-HBV PRE 协同跨核转运途径抑制HBV复制的机制研究(编号:81672009),张继明,课题